Definitive Healthcare Corp. (NASDAQ:DH) Given Average Rating of “Hold” by Brokerages

Definitive Healthcare Corp. (NASDAQ:DH) has been given a consensus recommendation of “Hold” by the nine research firms that are presently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $11.31.

DH has been the subject of several analyst reports. Canaccord Genuity Group cut shares of Definitive Healthcare from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Stifel Nicolaus dropped their price objective on shares of Definitive Healthcare from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 17th. Canaccord Genuity Group lifted their price objective on shares of Definitive Healthcare from $9.00 to $10.00 and gave the stock a “hold” rating in a research note on Thursday, February 29th. Barclays lifted their price objective on shares of Definitive Healthcare from $10.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Friday, March 1st. Finally, Needham & Company LLC cut shares of Definitive Healthcare from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in DH. Massachusetts Financial Services Co. MA raised its position in shares of Definitive Healthcare by 76.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,466,514 shares of the company’s stock worth $34,457,000 after acquiring an additional 1,496,652 shares in the last quarter. Conestoga Capital Advisors LLC increased its position in Definitive Healthcare by 12.1% in the 4th quarter. Conestoga Capital Advisors LLC now owns 5,521,137 shares of the company’s stock valued at $54,880,000 after buying an additional 595,280 shares in the last quarter. Vanguard Group Inc. increased its position in Definitive Healthcare by 6.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,331,543 shares of the company’s stock valued at $34,609,000 after buying an additional 254,726 shares in the last quarter. Raymond James & Associates increased its position in Definitive Healthcare by 41.6% in the 1st quarter. Raymond James & Associates now owns 844,814 shares of the company’s stock valued at $6,818,000 after buying an additional 248,266 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in Definitive Healthcare by 11.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,090,136 shares of the company’s stock valued at $8,710,000 after buying an additional 113,963 shares in the last quarter. 98.67% of the stock is owned by institutional investors.

Definitive Healthcare Stock Performance

Shares of DH stock opened at $7.33 on Tuesday. The stock has a market cap of $863.39 million, a P/E ratio of -4.12, a P/E/G ratio of 6.15 and a beta of 1.39. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.31 and a quick ratio of 2.31. The company has a fifty day moving average price of $8.32 and a two-hundred day moving average price of $8.31. Definitive Healthcare has a one year low of $5.53 and a one year high of $12.45.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.02). The firm had revenue of $65.93 million during the quarter, compared to analyst estimates of $66.01 million. Definitive Healthcare had a negative net margin of 80.40% and a positive return on equity of 0.43%. As a group, equities analysts predict that Definitive Healthcare will post 0.11 EPS for the current year.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.